Skip to main content
SpringerLink
Log in

Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Heparin-induced thrombocytopenia (HIT) syndrome is a catastrophic complication of heparin therapy that may result in arterial/venous thromboembolic events. The pathophysiology of HIT is mediated by the generation of a functionally and molecularly heterogeneous group of anti-heparin-platelet factor 4 (AHPF4) antibodies that cause platelet/endothelial cell activation/destruction. These AHPF4 antibodies may be of various subtypes and cause differential pathogenic responses during HIT. This study evaluated the differential prevalence and functionality of AHPF4 Ig subtypes (IgA, IgG, and IgM) in plasma samples obtained from clinically suspected HIT patients (n = 111) and two clinical trials. In these trials, a low-molecular-weight heparin, clivarin and unfractionated heparin (UFH) were used to treat deep-vein thrombosis (CORTES) and for prophylaxis of the orthopedic surgery (ECHOS). In the CORTES study, three randomized groups of patients (n = 312–328) received prophylactic treatment with either UFH or clivarin (o.d. or b.i.d.). In the ECHOS study, there were approximately 600 patients per group. Citrated plasma samples were analyzed for cumulative IgA/IgG/IgM and individual Ig subtypes of AHPF4 utilizing ELISA. Functionality of the ELISA-positive samples was ascertained by 14C-serotonin release assay. In clinically confirmed HIT patients (and UFH-treated CORTES and ECHOS samples), the Ig subtyping revealed a predominance of IgG AHPF4 antibodies in contrast to the asymptomatic high AHPF4 antibody titers, which were found to be mostly IgM and/or IgA subtypes. In the clivarin-treated patients in both trials, the prevalence of AHPF4 antibodies was found to be lower (2–3 fold, p < 0.01) in comparison to UFH group. In addition, the clivarin-treated patients with positive AHPF4 antibodies were found to be predominantly of the non-functional type and were found in the order of IgM > IgA > IgG. Together, these observations demonstrate that ELISA-detectable IgG subtype in UFH-treated patients may be more likely to cause functional/pathologic responses during HIT syndrome. Thus, determination of IgG subtype of AHPF4 antibodies during HIT syndrome may be crucial in the diagnosis; however, the relevance of the pathologically non-functional (IgA and/or IgM) antibodies and the overall mechanism(s) of these HIT-associatied antibodies need further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amiral J, Bridey F, Wolf M et al.: Antibodies to macromolecular platelet factor 4 heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 73: 21–28, 1995

    Google Scholar 

  2. Brandt JT, Isenhart CE, Osborne JM et al.: On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 74: 1564–1572, 1995

    Google Scholar 

  3. Burgess JK, Lindeman R, Chesterman CN, Berndt MC: Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 91: 761–766, 1995

    Google Scholar 

  4. Carlsson LE, Santoso S, Baurichter G et al.: Heparin-induced thrombocytopenia: New insights into the impact of FcγRIIa-R-H-131 polymorphism. Blood 92: 1526–1531, 1998

    Google Scholar 

  5. Newman PM, Chong BH: Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96: 182–187, 2000

    Google Scholar 

  6. Lindhoff-Last E, Gerdsen F, Achermann H, Bauersachs R: Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 113: 886–890, 2001

    Google Scholar 

  7. Untch B, Ahmad S, Jeske WP et al.: Prevalence, isotype and functionality of anti-heparin-platelet factor 4 antibodies in patients clinically suspected for heparin-induced thrombocytopenia: The pathogenic role of IgG. Thromb Res 105: 117–123, 2002

    Google Scholar 

  8. Izban KF, Lietz HW, Hoppensteadt DA et al.: Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 25(suppl 1): 51–56, 1999

    Google Scholar 

  9. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 67: 27–30, 1986

    Google Scholar 

  10. Walenga JM, Jeske WP, Wood JJ et al.: Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol 36(suppl 1): 22–28, 1999

    Google Scholar 

  11. Ahmad S, Walenga JM, Jeske WP et al.: Functional heterogeneity of anti-heparin platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 5(suppl 1): S32–S37, 1999

    Google Scholar 

  12. Fabris F, Ahmad S, Cella G et al.: Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications — a review. Arch Pathol Lab Med 124: 1657–1666, 2000

    Google Scholar 

  13. Suh JS, Malik MI, Aster RH, Visentin GP: Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 54: 196–201, 1997

    Google Scholar 

  14. Amiral A, Wolf M, Fischer A-M, Boyer-Neumann C, Vissac A-M: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92: 954–959, 1996

    Google Scholar 

  15. Visentin GP, Malik M, Cyganiak KA, Aster RH: Patients treated with unfractionated heparin during open-heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med 128: 346–347, 1996

    Google Scholar 

  16. Pouplard C, Amiral J, Borg JY et al.: Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 99: 273–280, 1997

    Google Scholar 

  17. Warkentin TE, Levine MN, Hirsh J et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330–1335, 1995

    Google Scholar 

  18. Warkentin TE, Sheppard JA, Horsewood P et al.: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96: 1703–1708, 2000

    Google Scholar 

  19. Lee SH, Liu CY, Visentin GP: Heparin-induced thrombocytopenia: Molecular pathogenesis. Int J Hematol 76(suppl 1): 346–351, 2002

    Google Scholar 

  20. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV: Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 344: 626–631, 2001

    Google Scholar 

  21. Kakkar VV, Hoppensteadt DA, Fareed J et al.: Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 99: 1965–1970, 2002

    Google Scholar 

  22. Haas S, Breyer H-G, Bacher HP et al.: Prevention of severe venous thromboembolism following total hip or knee replacement: A randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). N Engl J Med (in press)

  23. Visentin GP, Moghaddam M, Beery SE et al.: Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 138: 22–31, 2001

    Google Scholar 

  24. Aldabbagh A: Differential pathogenic profile of anti-Heparin-PF4 antibodies in patients treated with unfractionated and low-molecular-weight heparins: Implications in the management of heparin-induced thrombocytopenia. M.S. Thesis, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL, 2000

    Google Scholar 

  25. Kelton JG, Smith JW, Warkentin TE et al.: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83: 3232–3239, 1994

    Google Scholar 

  26. Horsewood P, Hayward CPM, Warkentin TE, Kelton JG: Investigation of the mechanisms of monoclonal antibody induced platelet activation. Blood 78: 1019–1026, 1991

    Google Scholar 

  27. Slupsky JR, Cawley JC, Griffith LS, Shaw ARE, Zuzel M: Role of FcγRIIa in platelet activation by monoclonal antibodies. J Immunol 148: 3189–3194, 1992

    Google Scholar 

  28. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332: 1374–1376, 1995

    Google Scholar 

  29. Chong BH: Heparin-induced thrombocytopenia. Br J Haematol 89: 431–439, 1995

    Google Scholar 

  30. Aird WC, Escobar B, Mark EJ: A 53-year-old man with a myocardial infarct and thromboses after coronary artery bypass grafting: Heparin-induced thrombocytopenia associated with extensive thrombosis (white-clot syndrome). N Engl J Med 346: 1562–1570, 2002

    Google Scholar 

  31. Warkentin TE, Kelton JG: Heparin-induced thrombocytopenia. Prog Hemost Thromb 10: 1–34, 1991

    Google Scholar 

  32. Amiral J, Marfaing-Koka A, Poncz M, Meyer D: The biological basis of immune heparin-induced thrombocytopenia. Platelets 9: 77–91, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, USA

    Sarfraz Ahmad, Brian Untch, Debra A. Hoppensteadt, Harry L. Messmore, Jeanine M. Walenga & Jawed Fareed

  2. Florida Hospital Cancer Institute, Center for Hemostasis and Thrombosis, 2501 N. Orange Avenue, Suite 786, Orlando, FL, 32804, USA

    Sarfraz Ahmad & Sylvia Haas

  3. Knoll AG Pharmaceuticals, Research and Development, Ludwigshafen, Germany

    Frank Misselwitz

Authors
  1. Sarfraz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian Untch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Debra A. Hoppensteadt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frank Misselwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Harry L. Messmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeanine M. Walenga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jawed Fareed
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmad, S., Untch, B., Haas, S. et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis. Mol Cell Biochem 258, 163–170 (2004). https://doi.org/10.1023/B:MCBI.0000012852.60500.30

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:MCBI.0000012852.60500.30

Search

Navigation